个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Profile of Next-Generation Sequencing (NGS) on MET exon 14 Skipping Mutation and MET Amplification in Lung Cancer: A Calibration Project in China

| 认领 | 导出 |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE

作者：
Wu, W.[1] * ; Wu, C.[1] ; Liu, Y.[2] ; Zhang, Z.[3] ; Liang, Z.[4,5] ;
机构： [1]Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Pathol, Shanghai, Peoples R China [2]Sichuan Canc Hosp & Inst, Dept Pathol, Chengdu, Peoples R China [3]Nanjing Med Univ, Affiliated Hosp 1, Dept Pathol, Nanjing, Peoples R China [4]Peking Union Med Coll Hosp, Mol Pathol Res Ctr, Dept Pathol, Peking Union Med Coll, Beijing, Peoples R China [5]Chinese Acad Med Sci, Beijing, Peoples R China
出处：
ISSN：

关键词： MET alterations Next generation sequencing assay External quality assessment

语种：
外文
WOS：
中科院(CAS)分区：
出版当年[2021]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 呼吸系统
最新[2023]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 呼吸系统
JCR分区：
出版当年[2021]版：
Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM
最新[2023]版：
Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

影响因子： 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者：
第一作者机构： [1]Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Pathol, Shanghai, Peoples R China
推荐引用方式(GB/T 7714)：
Wu W.,Wu C.,Liu Y.,et al.Profile of Next-Generation Sequencing (NGS) on MET exon 14 Skipping Mutation and MET Amplification in Lung Cancer: A Calibration Project in China[J].JOURNAL OF THORACIC ONCOLOGY.2021,16(10):S1146-S1147.
APA：
Wu, W.,Wu, C.,Liu, Y.,Zhang, Z.&Liang, Z..(2021).Profile of Next-Generation Sequencing (NGS) on MET exon 14 Skipping Mutation and MET Amplification in Lung Cancer: A Calibration Project in China.JOURNAL OF THORACIC ONCOLOGY,16,(10)
MLA：
Wu, W.,et al."Profile of Next-Generation Sequencing (NGS) on MET exon 14 Skipping Mutation and MET Amplification in Lung Cancer: A Calibration Project in China".JOURNAL OF THORACIC ONCOLOGY 16..10(2021):S1146-S1147

相关文献

[1]Validating a targeted next-generation sequencing assay and profiling somatic variants in Chinese non-small cell lung cancer patients [2]Performance validation of an amplicon-based targeted next-generation sequencing assay and mutation profiling of 648 Chinese colorectal cancer patients [3]Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION) [4]Challenges in next generation sequencing of homology recombination repair genomic variants in prostate cancer: A nationwide survey and calibration project in China [5]Long-Term Efficacy, Safety, and Subgroup Analysis of Savolitinib in Chinese Patients With NSCLCs Harboring MET Exon 14 Skipping Alterations [6]The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable [7]Circulating tumour DNA biomarkers in savolitinib-treated patients with non-small cell lung cancer harbouring MET exon 14 skipping alterations: a post hoc analysis of a pivotal phase 2 study [8]Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study. [9]医院后勤精细化管理策略研究 [10]个性化目标教学在神经外科护理实习生带教中的应用

资源点击量：52808 今日访问量：1 总访问量：4560 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号